Vol. 27, Issue 8, 855-859, August 1999

SHORT COMMUNICATION
A Double-Peak Phenomenon in the Pharmacokinetics of Alprazolam after Oral Administration

Yunxia Wang, Amit Roy, Lei Sun, and Chyan E. Lau

Department of Psychology,
Rutgers University,
Piscataway, New Jersey (Y.W, C.E.L.);
Environmental and Occupational Health
Sciences Institute,
University of Medicine and
Dentistry of New Jersey
Robert Wood Johnson Medical School and
Rutgers University, Piscataway, New Jersey (A.R.);
and Department of Chemistry, Rutgers University,
Piscataway, New Jersey (L.S.)

The pharmacokinetics of alprazolam (ALP) after i.v. and p.o. administration in rats were characterized. ALP decayed biexponentially after the i.v. dose (1.25 mg/kg), but the concentration-time profiles after the p.o. doses (7 and 12.5 mg/kg) exhibited a double-peak phenomenon. The presence of two peaks was confirmed by statistical analysis of the serum concentration data of ALP, as well as by observed double peaks in the serum concentration-time profiles of the two active metabolites (-hydroxyalprazolam and 4-hydroxyalprazolam). An absorption model incorporating a delay site is proposed to describe the data, and the absolute oral bioavailability is estimated to be about 30%. The two peaks were ~80 to 115 min apart, and there was a delay in the absorption of close to 80% of oral ALP, regardless of dose. We hypothesize that the mechanism underlying the double-peak phenomenon is due to reduction in gastric motility caused by the muscle relaxant effect of ALP. This hypothesis is supported by the observed longer delay in the appearance of the second peak at the higher p.o. dose. Enterohepatic recycling is precluded from being the underlying mechanism, because of the presence of double peaks after the p.o. doses but not after the i.v. dose. This is the first reported case of double peaks for oral ALP, and this phenomenon has not been reported for other benzodiazepines. The double-peak phenomenon caused by the hypothesized mechanism may have important therapeutic and drug interaction implications, especially because benzodiazepines are commonly coadministered with other drugs.